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Onset 
 
 
Sonia C. Youhanna 
 
ABSTRACT 
 
 
Coronary Artery Disease (CAD) is a multifactorial disease with acquired and 
inherited components. This study aim was to evaluate the function of MPO in 
discriminating angiographic CAD result, to demonstrate the role of SNPs 
599839-12487736 in early onset of CAD and to isolate the role of genetics by 
exploring the concomitant effect of consanguinity and disease family history in 
determining risk and age at diagnosis of CAD.  CAD was determined by cardiac 
catheterization. Analysis of variance, chi square, spearman’s correlation, Gensini 
score and logistic regression tests were constructed to isolate genetic and 
environmental impacts of family history, to determine the genetic impact on 
disease expression and age at diagnosis of CAD, and to clarify the role of MPO in 
stenosis severity. Family history of CAD and age showed significant risk for 
young age at diagnosis of CAD (p <0.001).Consanguinity did not appear to 
promote risk of CAD (p =0.375 category 3), but rather significantly associated 
with young age of disease diagnosis (p <0.001).MPO levels were not statistically 
correlated with Gensini scores. Only rs599389 was significantly associated with 
the early onset of CAD. The minor allele G of rs599389 is a protector for early 
 
onset of CAD while family history of CAD is a strong promoter of young age at 
diagnosis.    Furthermore, parental consanguinity in the presence of family history 
lowers the age of disease diagnosis significantly for CAD, emphasizing the role of 
strong genetic CAD modifiers.  These results place the age of disease diagnosis as 
an important screening factor in genetic disease association studies.  
 
Keywords: Coronary artery disease, single nucleotide polymorphism, 
inflammation, Myeloperoxidase, stenosis, Family History, Consanguinity, 
atherosclerosis. 
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 1. Introduction 
1.1. Epidemiology of Coronary artery disease. 
 
Despite the significant improvement that has been achieved in the 
management of cardiovascular diseases, atherosclerosis remains the leading 
cause of illness, disability and death in modern countries(Figure1)(Patel, 
2008) It is a progressive and complex disease characterized by the buildup of 
lipid and fibrous particles in the arteries with acquired and inherited 
components being implicated in its development(Nordlie, 2005). CAD is 
promoted by many risk factors. While most of these can be substantially 
controlled through lifestyle changes, such as dietary choices and involvement 
in physical activity, inherited causes such as genetic make-up and family 
history of the disease are not modifiable.  
 
 
 
1 
 
 Figure 1: Global Burden of CAD. In order to characterize correlations 
between CAD and geography a frequency map of ischemic heart disease 
burden was created using the WHO global(WHO, 2011). 
1.2. Role of inflammation in CAD. 
 
It is believed that there are complex interactions between arterial wall cells 
and blood through the exchange molecular messages(P. Libby, Theroux, P., 
2005) In the presence of particular risk factors, complex interactions may 
lead to endothelial dysfunction, plaque formation and rupture, which are 
directly involved in CAD occurrence. Inflammation, being involved in all 
previously mentioned steps, was found to be a major contributor to 
atherosclerotic plaque development from early lipid deposition to plaque 
rupture.  
1.2.1. Atherosclerotic lesion formation. 
 
Atherosclerotic lesion formation starts when endothelial cells undergoing 
inflammatory variations (due to glycoxidation products incriminated in 
hyperglycemia or pro-inflammatory cytokines) increase the expression of 
adhesion molecules thus increase leukocyte adhesion to arterial wall. 
Adherent leukocyte mainly monocytes and T lymphocytes transmigrate to 
the arterial intima by diapedesis. This phenomenon is mediated by the 
expression of chemoattractant cytokines coupled with risk factors of 
atherosclerosis(P. Libby, Theroux, P., 2005). Migrating monocytes reaching 
the intima acquire tissue macrophages characteristics essentially binding 
oxidized LDL. This combination gives rise to lipid-containing foam cells 
that secrete pro-inflammatory cytokines hence intensifying local 
inflammatory response to the region (P. Libby, 2002). Simultaneously, in the 
region of inflammation, proliferation of smooth muscle cells, accumulation 
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 of foam cells and degradation of matrix through proteolysis result in 
vulnerable plaque generation(Watkins, 2006)(Figure2). 
 
It is suggested that plaque rupture and destabilization are mediated by 
inflammatory actions as plaque erosion focus is marked by activated 
monocytes and T lymphocytes (Sanjay  Patel, 2008). Clinical manifestation 
and disease outcome are dictated by plaque stability: when plaque remains 
stable it will progressively narrow the lumen of the artery and reduce blood 
flow, clinically this will cause stable angina, in contrast when plaque is 
ruptured suddenly this will cause rapid occlusion of the artery which is 
manifested clinically by myocardial infarction(Watkins, 2006).  
1.2.2. Myeloperoxidase and CAD. 
 
Myeloperoxidase (MPO) is an enzyme produced in the bone marrow during 
myeloid differentiation. It is accumulated in neutrophils and monocytes 
before their entry in circulation and it is released during inflammation upon 
leukocytes activation and degranulaiton (Zhang et al., 2001). Despite its 
antimicrobial activity MPO has a strong pro-inflammatory feature promoting 
tissue injury through oxidative damage at inflammation site(Borges, 2009). 
This has been confirmed by immunohistochemistry of atherosclerotic lesions 
showing high levels of MPO and by mass spectrometry showing oxidation 
products. The role of MPO in plaque rupture has been well established; it 
acts as a catalytic agent in LDL oxidation resulting in avid uptake of 
oxidized LDL by macrophages which leads to cholesterol deposition and 
foam cell formation. In addition, MPO can alter vasomotor tonus via its 
ability to use endothelial nitric oxide as a physiological substrate 
(Figure2)(Esporcatte, 2007). Based on several epidemiological studies, MPO 
seems to have the potential to become one of the most reliable ischemic 
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 biomarkers. Consequently MPO plays an important role in diagnosis and 
prognosis of CAD, particularly that elevated MPO levels are significantly 
associated with cardiovascular disease risk factors (Vita, 2004). A study 
conducted on EPIC-Norfolk population of healthy subjects revealed that risk 
for CHD increases directly in subjects with higher MPO levels measured at 
baseline (Meuwese et al., 2007). In another study performed on acute 
coronary syndrome patients, myocardial infarction and death accounted for 
participants with elevated MPO serum levels(Loria, 2008). Marshall et al. as 
well were able to identify high risk troponin-negative patients using MPO 
levels as a tool (Corson, 2009). Conversely, Stephanescu et al. could not 
demonstrate an independent association between MPO and all cause 
mortality in a prospective study done on patients with stable CAD. 
Moreover, Lucio et al. indicated in their study that MPO levels were not  
significantly associated with Gensini score which denies any link between 
MPO expression and atherosclerotic lesion severity(de Azevedo Lucio et al., 
2011).  
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Figure 2: Summary of the inflammatory processes and the role of MPO 
in atherosclerotic lesion formation. Inside the intima, reactive oxygen 
species (ROS) induce modifications in the penetrating LDL (mmLDL) which 
will lead to monocytes migration into the vascular wall. Migrating 
monocytes will undergo differentiation into macrophages that are able to 
recognize oxidized LDL (oxLDL) consequently the formation of foam cells. 
In a state of inflammation, macrophages release MPO that utilize NO, 
chloride, and thiocyanate as a substrates enhancing the development of 
Myeloperoxidase-derived reactive species (MDRS). A decrease in 
endothelial NO may induce impaired vasodilation. MDRS promote 
atherosclerosis through enhancing formation of both species oxLDL  and 
oxidized HDL leading to impairment in  HDL’s protective role, it also causes 
plaque destabilization by weakening the fibrous cap(Schindhelm, 2009). 
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 Through its role in plaque initiation and plaque rupture inflammation plays 
an important role in CAD development but there are several other triggering 
factors that can be implicated in CAD occurrence such as genetic factors.  
We will examine the role of specific genetic variants that can be implicated 
in CAD and CAD early onset. 
 
 1.3. Genetics in CAD 
 
A small proportion of CAD cases can be attributed to rare, highly penetrant 
monogenic effects (Helgadottir et al., 2005), but in most cases the disease is 
caused by the cumulative effect of multiple genetic mutations and the 
environment. Lately genetic studies dedicated to identify new complex-
disease causing variants are focusing on associations between Single 
nucleotide polymorphisms (SNP) and disease risk in genome wide 
association studies (GWAS). GWAS succeeded to identify several loci to be 
associated with either predisposition to CAD or protection against 
CAD(Consortium., 2007).  
 
1.2.1. Proline/serine-rich coiled-coil 1 (PSRC1) 
 
The 599839 variant  located in 3’untranslated region of the PSRC1 gene was 
found to be in linkage disequilibrium with several SNPs on the chromosomal 
locus 1p13.3 which encompasses 4 genes (proline/serine-rich coiled coil 
protein 1(PSRC1), cadherin, EGF LAG seven-pass G-type receptor 2 
(CELSR2),myosin binding protein H-like (MYBPHL) and sortilin 1 
(SORT1)(Kleber et al., 2010). This region has been associated with CAD in 
many replication studies (Willer et al., 2008) while others indicated no 
association(J. Karvanen et al., 2009).the minor allele of rs599389 acts on 
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 lowering LDL plasma levels thus decreasing CAD risk. This action is 
mediated by an increased expression of SORT1gene in the liver therefore 
increased expression of Sortilin on hepatic cells(Linsel-Nitschke et al., 
2010). The prominent expression of sortilin protein will lead to an increase in 
LDL uptake by the liver and a decrease in LDL plasma levels.. It has also 
been established that this locus is consistently linked to low density 
lipoprotein cholesterol (Aulchenko et al., 2009). Shadt et al. reported a 
significant positive association between PSRC1 gene and plasma LDL levels 
but a significant negative association among CELSR2 SORT1 and plasma 
LDL levels (Schadt et al., 2008). The SNP 599839 showed high correlation 
with CAD and LDL-C in several studies conducted in different populations: 
Markus et al. highlighted the protective role of the G allele in CAD and 
LDL-C metabolism in European population (Kleber, et al., 2010). Bressier et 
al. demonstrated as well the protective role of G allele against CAD 
occurrence in young subjects in European population but this significance 
was abolished when the author corrected for LDL-C (Bressler, 2010). Same 
findings were reported by the coronary artery disease consortium (Amouyel 
et al., 2009). Replication of the above findings in the Japanese population 
done by Nakayam et al. were in accordance with the European results 
(Nakayama et al., 2009). The minor allele G of the 599839 SNP besides 
being associate with low LDL-C serum levels it was suggested to be 
associated with the early onset of CAD in the Chinese population(Huang, 
2008). Conversely, Karvanen et al. were not able to find an association 
between CAD incidence and rs599839 in a prospective cohort from Finland, 
Sweden, France and Northern Ireland (J. Karvanen, Silander, K., Kee, F., 
Tiret, L., Salomaa, V., Kuulasmaa, K., Wiklund, P. G., Virtamo, J., Saarela, 
O., Perret, C., Perola, M., Peltonen, L., Cambien, F., Erdmann, J., Samani, 
N. J., Schunkert, H., Evans, A., 2009) 
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1.2.2. SREBF cleavage activation protein (SCAP)  
The SCAP gene located on chromosomal locus 3p21.3, has 23 exons and 
encompasses a SNP in exon 16: rs1248773 (Iwaki, 1999). SCAP forms a 
complex with sterol regulatory element binding transcription factor (SREBF) 
which causes the activation of SREBF by releasing the amino-terminal 
transcription activation domain of the SREBF. The active form of SREBF 
can travels to the nucleus where it binds to promoters of more than 30 target 
genes all implicated in lipid metabolism and LDL-receptors 
expression(Rawson, 2003). In a Finish study, the SCAP variant was found to 
be associated with early sudden cardiac death (Fan et al., 2008). Friedlander 
et al. were not able to demonstrate any association between SCAP 
polymorphism and MI but highlighted a modifying role of this variant to the 
association of SREBR-2 genotype with MI risk in men (Friedlander et al., 
2008). A lack of association between this variant and early onset of CAD in a 
Chinese population has been reported by Chen et al. (Chen, 2010).  
CAD has long been known to run in families, the role of consanguinity in 
such a disease is still controversial for this reason we will assess the function 
of consanguinity as risk factor for early onset of CAD in our Lebanese 
population.   
 
1.3. Consanguinity and CAD. 
Family history of CAD is considered to be a major risk factor in disease 
development, (M. T. Scheuner, Wang, S. J., Raffel, L. J., Larabell, S. K., 
Rotter, J. I., 1997) not only as a result of inherited  susceptibility genes, but 
also because family members tend to share similar lifestyles. All of this may 
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 exacerbate individuals’ susceptibilities to(M. T. Scheuner, 2004). Yasar et al. 
demonstrated in their study that family history of CAD was the third most 
important CAD risk factor in both genders aged less than or equal to 45 years 
old (Yasar et al., 2008). Blood relatives share a greater proportion of the 
same gene variants than non relatives. Consanguinity (defined as individuals 
whose parents are blood relatives) has been demonstrated to play a role in the 
development of CAD in young adults, independent of family history of the 
disease, through enhanced autozygous inheritance of recessive CAD 
susceptibility gene variants (Abu-Amero, 2006) It is more likely that 
descendants of a consanguineous marriage inherit the same gene variant or 
variants from each of their parents, and thus, are more likely to have similar 
“gene determined” health outcomes(Barlow-Stewart, 2007). Consanguineous 
marriages are common in third world countries(Bittles, 2010) In the Arab 
world, consanguinity is common, with 50.3% of marriages being 
consanguineous in Jordan(Khoury, 1992), 54.3% in Kuwait(Al-Kandari, 
2011), 28.9% in Egypt (Hafez, 1983) and 25% in Lebanon(Khlat, 1988) .  
 
1.4 Studying CAD in the Lebanese population from different 
perspectives. 
 
MPO correlation with CAD severity has been extensively explored in 
different populations. Scarce information exists on the association between 
serum MPO levels and disease severity in the Lebanese population. We will 
explore and try to clinically understand the association of MPO with stenosis 
severity in Lebanese CAD patients in the first section of this work. 
Replication of  SNP studies has led to different results in many population 
thus it is important to replicate genetic findings in our Lebanese population   
in addition, investigating the genetic association of specific SNPs with early 
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 onset of CAD in the Lebanese population in the second part of this study will 
help  to develop prognostic tool and to reduce disease burden. Considering 
CAD in the highly consanguine Lebanese population provides a unique 
opportunity to explore the impact of consanguineously enhanced 
homozygosity and disease family history on CAD and its early diagnosis, 
therefore providing new information about mechanisms driving the disease 
etiology.  
 
 
 
 
 
 
 
2. Materials and methods 
2.1. Study Subjects. 
 
This study consists of 4284 subjects who underwent cardiac catheterization 
consecutively between May 2006 and June 2009 at 2 major university 
hospitals in Lebanon. Catheterization was prompted for MI (12.7%), 
unstable angina (29.01%), or other reasons (58.3%). Patients who accepted 
enrollment in the study signed the study’s consent form after it was 
explained to them. In an interview, patients were asked to answer general 
questions about their medical status, use of medication and family history of 
CAD as well as other diseases. In addition, all patients’ medical charts were 
reviewed for data collection on demographics, medical history, surgical and 
pharmacological interventions and laboratory test results. All study patients 
underwent coronary catheterization by Judkins’ technique. A blood sample 
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 of 20cc was collected in a sterile syringe from the femoral artery 
catheterization site of every patient consenting to enroll in the database.  
Blood samples were labeled by patient codes and transported to a nearby 
Clinical Research Unit for centrifugation, serum and plasma separation and 
storage at -80°C. DNA was extracted from 5cc of the blood using DNA 
blood extraction protocol developed in the genomics lab. 
Coronary angiograms were performed as a diagnostic procedure for clinical 
indications and not for the purposes of the study itself; however the results of 
the angiograms were utilized as our main outcome variable. Angiography 
was performed to visualize the left main coronary artery (LM), the left 
anterior descending artery (LAD), the left circumflex coronary artery (LCx) 
and the right coronary artery (RCA). All coronary arteries were imaged from 
different angles. To evaluate the degree and severity of coronary artery a 
modified version of Gensini score was applied to the samples that were 
selected for MPO analysis(Gensini, 1983). Calculation of the Gensini score 
was done by attributing a severity score to every coronary stenosis based on 
the degree of luminal narrowing and its geographic importance. Reduction in 
lumen diameter was estimated (reductions of ≥50%, 50 to 75% and< 70% 
occlusion were assigned Gensini scores of 1, 3, and 6 respectively). A 
multiplier was assigned to every main vascular segment based on the 
functional significance of the myocardial area supplied by that segment: 5 for 
the left main coronary artery; 2.5 for the proximal segment of the left 
anterior descending (LAD) coronary artery; 2.5 for the proximal segment of 
the circumflex artery; 1.0 for the right coronary artery.  
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2.2. Cases and Controls selection 
 
Patients with a normal angiogram were considered as controls, and were 
classified as CAD category 1. The remaining patients were grouped 
according to the extent of coronary artery stenosis: CAD category 2 
comprised patients with ≤ 50% stenosis in any coronary artery and CAD 
category 3 patients with > 50 % stenosis in any of the coronaries(Abchee, 
2006). The age at diagnosis was defined as age of the subject when CAD was 
first identified by catheterization. The age at first procedure (PTCA:  
Percutaneous transluminal coronary angioplasty; CABG: Coronary Artery 
Bypass Graft) was considered the age at diagnosis for recruited patients with 
prior history of CAD.  In CAD category 3 patients, young age at diagnosis 
was defined as age at diagnosis less than or equal to 50 years for males, and 
less than or equal to 55 years for females (Hauser, 2003). Family history of 
CAD (FxCAD) was identified if siblings, parents, cousins, aunts or uncles 
had a clinical documentation CAD diagnosis. Parental consanguinity was 
categorized as follows: no consanguinity (C0); parents are first degree 
cousins (C1); parents are at least second degree cousins (C2). Other variables 
identified for each patient included diagnosis of diabetes (DxDiabetes), 
diagnosis of hyperlipidemia (DxHL), and diagnosis of hypertension (DxHT).  
82 subjects refused to participate in the study when they were informed that 
their blood specimen might be further analyzed in studies relating to CAD. 
The Institutional Review Boards of the Lebanese American University and 
the American University of Beirut approved the study protocol. 
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2.3. ELISA for MPO measurement. 
 
MPO plasma levels were measured in 275 samples of patients diagnosed 
either with acute coronary syndrome (ACS) or unstable angina (USA). 
Subjects were selected from the above cited population. All plasma samples 
were analyzed at a single time point. Thawed samples were diluted1:50 and 
placed in 96-well plates. Plasma MPO concentrations were measured by 
enzyme-linked immunosorbant assay (ELISA) colorimetric technique (R&D 
System Inc., Minneapolis, MN; minimum detectable dose (MDD) This test is 
based on a sandwich technique in which two monoclonal antibodies are 
directed against separated MPO antigens.  The minimum detection range was 
set at 0.026 ng/ml of MPO ranged Standard curve for MPO were derived 
using standard concentrations (provided by manufacturer) and optical density 
measured at 450nm wavelength and 540 nm wavelength for correction. 
2.4. SNPs selection 
 
Two SNPs accounted to be significantly associated with CAD and its early 
onset in several studies were selected from NCBI Pubmed database, The 
SNPs were custom made by Applied Biosystems.SNP genotyping was 
performed on 1950 samples chosen randomly from the above mention 
population. 
 
2.5. SNPs genotyping assay 
To determine genotypes of the selected SNPs (599839 and 12487736) 
5’exonuclease assay (Taqman®) was carried out on the Applied Biosystems 
7900HT Fast Real Time PCR System (Figure 3) (Applied Biosystems, Foster 
City, CA). Primer and probe sets were pre-designed by Applied Biosystems. 
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 PCR reaction was performed on 1 to 20ng of previously extracted DNA 
using 9.2µl 2X TaqMan Universal PCR Master Mix (Applied Biosystems) 
and 0.8 µl of 20x SNP Ggenotyping assay containing  primers the TaqMan 
MGB (minor grove binder) probes (TaqMan pre-designed SNP genotyping 
assay, Applied Biosystems) Cycling parameters were as follow: activation of 
the enzyme at 95°C for 10min, DNA denaturation at 95°C for 15sec, 
annealing and extension steps performed at60°C for 1min. Denaturation as 
well as annealing and extension steps were repeated for 45 cycles. 
Subsequently fluorescence values in each well are plotted generated by the 
SDS 2.1 software (System Detection Software) indicating the alleles present 
in each well. 
 
 
a-The TaqMan MGB probe (6-FAM dye-labeled) anneals to a specific 
complementary sequence between the forward and reverse primer sites.   
 
 
 
b- When the probe is intact and both dyes (reporter dye and quencher) are in 
proximity fluorescence of the reporter is suppressed. 
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c- Cleavage of the DNA by polymerase causes separation of the reporter dye from 
the quencher dye resulting in increased fluorescence by the reporter.  
 
 Figure 3: The 5´ nuclease assay process (ABI, 2004).  
 
 
2.6. Statistical Analysis 
 
Categorical data were expressed as frequencies. Continuous parametric data 
were expressed as means ± SD while non parametric variables such MPO 
levels and Gensini score were expressed as median. Comparison of 
continuous variables between groups was performed using univariate 
analysis of variance (ANOVA).  Associations between categorical variables 
were examined by chi-square testing or logistic regression analysis. The 
association between plasma MPO levels and the Gensini score was assessed 
using Spearman’s correlation coefficient and Mann Whitney test. A 
logarithmic transformation was applied to the variable MPO due to its non-
normal distribution.   
Fx CAD and consanguinity were evaluated as risk factors for disease by 
comparing subjects with no stenosis (CAD category 1) to subjects having 
greater than 50% stenosis (CAD category 3).In the consanguinity section 
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 patients without prior history of CAD and who were newly diagnosed with 
>50% stenosis (CAD category 3) were subdivided into 4 groups according to 
their risk factor status. Patients in subgroup 1 had no observed type 2 
diabetes, hypertension, hyperlipidemia, Fx CAD, or consanguinity. Patients 
in subgroup 2 had at least one of the following risk factors: type 2 diabetes, 
hypertension, or hyperlipidemia, but no Fx CAD or consanguinity. Patients 
in subgroup 3 had Fx CAD as their only risk factor, while patients in 
subgroup 4 had parental consanguinity in addition to Fx CAD. These patients 
were further characterized according to Fx CAD (f0: no Fx CAD; f1: Fx 
CAD in siblings, parents, or second-degree relatives) and parental 
consanguinity status. Gender differences in onset and development of CAD 
and myocardial infarction are well documented (Lewis, 2002). Thus, we used 
gender control for stratification to eliminate this confounding variable. 
Logistic regression (LR) analyses were performed to estimate the impact of 
diabetes, hypertension, hyperlipidemia, smoking, BMI, Fx CAD and 
consanguinity on (young age at diagnosis)YADCAD. This LR was 
performed to specifically predict DxCAD and YADCAD (males, females, 
and pooled) from DxD, DxHT, DxHL, BMI, smoking, Fx CAD, and 
consanguinity. Analyses of these results were also stratified by gender. This 
analysis can provide insight into interactions and possible gender related 
confounding, which may reflect both genetic components and gender-
dependent rates of diagnosis leading to catheterization. 
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 3. Results 
3.1. MPO results: 
The MPO subgroup comprises 275 patients with mean age of 58.42; more 
than 60% of the population is males, around 24% are diabetics and more than 
50 % are hypertensive. The majority are smokers (63, 1%) and tend to be 
obese (mean BMI 29.1%). This population seems to have a controlled 
glycemia since mean fasting blood sugar (FBS) is 113mg/ml and elevated 
levels of MPO (mean 509ng/ml) (Table1). 
 
Table 1: baseline clinical and baseline characteristics. 
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 Figure 5: Box-whisker plots of MPO levels versus severity scores. Lines 
within boxes represent median levels of both variables. 
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 Median MPO and Gensini score were 5.42ng/ml and 3.5 units 
respectively(Figure 5). Patients with median Gensini score ≤3.5 showed 
median MPO of 5.51 whereas patients with median Gensini score >3.5 had 
median MPO of 5. 23(p=0.54). When patients were stratified by median 
MPO levels, subjects with median MPO≤ 5.42 had median Gensini score of 
5.8 while patients with median MPO >5.42 showed median Gensini score of 
2.75(p=0.65).Spearman’s correlation coefficient did not show a significant 
association between MPO levels and Gensini scores (p = 0.53). No 
significant association were observed between MPO levels and selected 
variables (gender, diabetes, hypertension, hyperlipidemia, WBC, CRP levels 
and Gensini score)(Table2).There was no significant association between 
MPO serum levels and Gensini scores. 
 
Table 2: logistic regression analysis of the relationship of independent 
variables with the natural logarithm of the MPO 
 
 
3.2. SNPs results: 
The distribution of genotypes and alleles of both SNPs (599389, 12487736) 
among the 3 CAD groups was not statistically significant; there was no 
association between genetic polymorphisms of the above mentioned SNPs 
and CAD categories. Even considering several genotypic distribution models 
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 (A dominant model, G dominant model, C dominant model and T dominant 
model) we were not able to detect any significant association (Tables3a,3b). 
Comparison of genotype distribution, within several models, between CAD 
category 2 vs CAD category 3 was not significant for SNP 599389 and 
12487736 respectively same results were observed when genotypes were 
compared among CAD category 1 vs CAD category 3(Table4). 
 
Table 3a: Distribution of genotypes and alleles of rs599389 among CAD 
categories. 
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Table 3b: Distribution of genotypes and alleles of rs12487736 among 
CAD categories. 
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Table 4: Significance of genotype distribution comparison of SNP 
599389 and SNP 12487736 among CAD categories.  
 
*Comparison between CAD category 2vs CAD category 3 
# Comparison between CAD category 1vs CAD category 3 
 
To study the role of these 2SNPs in early onset of CAD we selected subjects 
with sever stenosis (CAD category3) and compared the age of onset among 
genotype categories. Results were as follow: 
There was no significant association between age of onset and SNP 
12487736(p=44) whereas SNP 599389 showed a significant association (p= 
0.03). The age of onset was the lowest within the heterozygote group (GA 
mean age of 58.0±11) compared to the two homozygote groups (AA mean 
age of 60.1±11.3, GG mean age of 62±8.7). 
When Subject’s age of onset, grouped in 2 categories early onset and late 
onset, (following the criteria mentioned in the material and method section) 
was compared within genotype distribution of both SNPs a p value of 0.016 
was obtained for the SNP 599389 while SNP 12487736 showed no 
significance (0.46). logistic regression analysis including SNP 599389 and 
age of onset category as outcome showed a p value of 0.026 for GA 
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 genotype with 95%CI  1.31-75.51 and GG genotype has p value of 0.048 
with 95% CI 1.01-57.12. 
To evaluate the impact of Fx CAD alone vs effect of SNP 599389 on early 
onset of CAD we compared the age of onset categories of the following 
groups who were negative for consanguinity: patients positive for FxCAD 
and have the protective genotype(GG) vs patients with no FxCAD but have 
the GA genotype p=0.02(table5). 
 
1. Table5: Impact of FxCAD vs genetics in early onset of disease 
 
  
Predisposing allele 
without Fx CAD 
FxCAD with protective allele  
total  
late onset   36  26  62 
early 
onset  22  2  24 
total        86 
  
 
3.3. Consanguinity results.  
Our study population consists of 2949 (68.8 %) men and 1335 (31.1 %) 
women with a mean age of 61.4 ± 11.2 for all subjects. Category 1 with 0 % 
stenosis (20.3 % of subjects) had a mean age of 56.5 ± 11.2, category 2 with 
≤ 50 % stenosis in any vessel (14.9 % of subjects) had a mean age of 61.3 ± 
11.0 and category 3 with > 50 % stenosis in any vessel (64.7 % of subjects) 
had a mean age of 63.0 ± 10.8 (Table 6) 
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Table 6: Summary statistics for ages of subjects among categories 
describing gender, reasons for catheterization, history of coronary 
artery disease interventions, and consanguinity. 
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As shown in  Figure 4, the mean age at diagnosis in subgroup 1 (no Fx CAD, 
no consanguinity, no DxDiabetes, no DxHL and no DxHT) was 62.8 years 
compared to 63.96 years for the risk factor subgroups 2 (having at least one 
of the following: DxDiabetes, DxHL and DxHT, but with no Fx CAD and no 
consanguinity). Taking family history of CAD as the only risk factor 
(subgroup 3) resulted in a further decrease in mean age of disease diagnosis 
(58.3 years).  The mean age at diagnosis was lowest, 54.8 years, when both 
consanguinity and Fx CAD were considered as the only two risk factors for 
CAD (subgroup 4). The differences in the mean age at diagnosis were 
significant when compared between the four risk groups (P< 0.001). 
Differences in mean ages at diagnosis among the various subgroups in Figure 
1 were investigated using Scheffe’s test. Despite the lower mean age at 
diagnosis for subgroup 1 compared to subgroup 2, the difference in mean age 
was not statistically significant. However, the differences in mean ages were 
statistically significant between subgroups 1 and 4 (p<0.001), 2 and 3 
(p<0.001) and 2 and 4 (p<0.001).   
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Figure 4. Differences in the mean age at diagnosis (±standard error of 
the mean) of CAD (>50% stenosis) among 4 subgroups of patients. 
Subgroup 1 had no observed type 2 diabetes, hypertension, hyperlipidemia, 
Fx CAD, or consanguinity; subgroup 2 had at least one of the following risk 
factors: type 2 diabetes, hypertension or hyperlipidemia, but no Fx CAD and 
no parental consanguinity; subgroup 3 had Fx CAD as the only risk factor; 
subgroup 4 had parental consanguinity and Fx CAD only. 
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 Figure 6 shows the age distribution of age at diagnosis for Category 3 
patients divided according to the presence or absence of Fx CAD and to the 
presence or absence of parental consanguinity. Among family history 
negative (F0) subjects, response to consanguinity appears to be weak, while 
response among family history positive subjects (F1) shows a significant 
reduction in age for first-degree consanguineous subjects, but insignificant 
responses among subjects with lesser degrees of consanguinity. 
 
 
 
 
Figure 6: Mean age distribution of disease diagnosis among CAD 
patients with ≥50% stenosis, given Fx and parental consanguinity status. 
f0: no Fx CAD; f1: presence of Fx CAD. In increasing order of 
consanguinity: c0: no consanguinity in parents; c2: parents are at least 
second-degree cousins; c1: parents are first-degree cousins. 
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 The impact of Fx CAD and consanguinity on lowering the YADCAD was 
further demonstrated by a LR controlling for DxD, DxHT and DxHL.  An 
increase in the OR from 1.52 (consanguinity alone) and 2.12 (FxCAD alone) 
to 3.37 was observed when both Fx CAD and consanguinity were considered 
in the LR model. 
We note that the distribution of ages at diagnosis among women is skewed 
relative to men, with a higher chance that women will show an age at 
diagnosis later than the average, as well as a corresponding reduction in early 
age at diagnosis (Table 7a). 
 
Table 7a. Predictors of  Average Age at diagnosis and young age at CAD 
diagnosis by Gender among subjects with sever stenosis using logistic 
regression (odds ratios).  
 
 
Diabetes, hypertension, hyperlipidemia, smoking, and family history of CAD 
were significantly associated with developing disease at CAD category 3 
levels, while consanguinity and BMI appeared to have no significant impact 
(Table7b).Interestingly, a hypertension diagnosis was significantly 
associated with reduced YADCAD across almost all categories, suggesting a 
protective role of antihypertensive medication or a more “healthy” lifestyle 
than a non-declared hypertensive.   
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 Diabetes was generally neutral in promoting YADCAD, while 
hyperlipidemia and BMI were significantly associated with early age of 
diagnosis overall and among men, but not significantly among women. 
Smoking was significantly associated with YADCAD across all categories. 
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 Table 7b. Adjusted odds ratios of family history of CAD and 
consanguinity as predictors of diagnosis and young age at diagnosis 
(YAD) of CAD, controlling for diabetes, hyperlipidemia, hypertension 
(HTN), BMI, smoking, age, and gender 
 
 
30 
 
 Surprisingly, the isolated interaction components anticipated from 
homozygous enhancement in family history of CAD and consanguinity were 
not associated with YADCAD (Table 7c). 
 
Table 7c. Predictors of young age of CAD diagnosis, by Risk Factors and 
their Interactions by Logistic Regression.  
 
FxCAD: Family history of CAD, Cons (parents are first degree relatives), OR: odds ratios, 
CI: 95% confidence intervals, P: one-tailed p-values.   
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 4. Discussion 
 
The manifestation of CAD follows a well choreographed series of events that 
includes the damaging of endothelial cells of the arteries and the gradual 
deposition of lipids in the sub-endothelial layers(Choudhury, 2004).  Age 
and family history are well known risk factors, but while a number of genetic 
markers have been suggested, the role of genetics has remained elusive. 
 
In the first part of this work we intended to search for an association between 
CAD severity and MPO levels in patients with high risk of CAD since all 
study subjects were clinically diagnosed with ACS or USA at the time of 
hospitalization. The severity of CAD, measured by Gensini score, was not 
worse within patients in the upper range of MPO median compared to 
patients in the lower range. We also reported no significant difference of 
MPO levels among patients with high Gensini score versus patients with low 
scores. There was no correlation of MPO levels and stenosis severity 
measured by Gensini score.  
Several epidemiological studies had reported an association between MPO 
and CAD while others demonstrated no significant correlation thus the 
relationship between MPO and CAD severity remains controversial. 
Duzguncinar et al. were able to find a significant but weak association 
(p=0.04) between MPO levels and CAD severity in stable patients with 
identified CAD (Duzguncinar, 2008). Conversely,  Kubala et al. did not 
demonstrate a statistically considerable difference in MPO levels between 
patients with documented CAD and CAD free patients(Kubala, 2008). A 
lack of association between MPO promoter polymorphism and severity in 
coronary lesions was reported by Wainstein et al.(Wainstein et al., 2010)the 
same author, in a different study, also confirmed a lack of association 
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 between MPO levels and angiographic severity using Gensini score(de 
Azevedo Lucio, et al., 2011). 
 
In the present study we tried to explore MPO function in classifying CAD 
severity detected by angiography in ACS patients. An increase in MPO 
levels in ACS patients may occur at early stages of the syndrome, even 
before substantial necrotic lesions highlighting possible plaque instability 
(Brennan, 2003). Thus, lesion initiation will not be detected by the traditional 
invasive strategy the coronary angiography. Even though this technique 
shows deficiency in providing information on plaque formation and 
morphology many clinical trials have demonstrated its importance in 
identifying and treating culprit lesions(Cannon et al., 2001). 
The none significance of association between MPO and stenosis severity in 
our study could be attributed to the fact that angiography-based Gensini 
scores allowed detection of the anatomical severity of atherosclerotic lesions 
without offering information neither on morphological nor on functional 
aspect of the lesions. Therefore inflammatory processes can be trigged even 
in mild obstructive CAD(de Azevedo Lucio, et al., 2011). 
       
Cardiovascular disease particularly premature cardiovascular morbidity and 
mortality is becoming a global health burden(Chen, 2010). While the 
heritability component of CAD was estimated to be 40 to 60 percent, 
reproducibility of these findings has been difficult (Bressler, 2010). In the 
second part of this work we tried to replicate findings that associated two 
SNPs (rs599389 and rs12487736) with early onset of CAD. For this purpose 
1950 samples were genotyped for those two polymorphisms. Bressler et al. 
demonstrated an association of SNP 599389 and CAD occurrence in young 
European population (<66 years) but the significance was eliminated when 
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 corrections for LDL and HDL were made (Bressler, 2010). In another study 
conducted on a European population, the association of the rs599839 to CAD 
was also established(Amouyel, et al., 2009). Kelber and coworkers also 
demonstrated a significant association of this SNP with CAD, and in 
addition, they were able to characterize the protective effect of the minor 
allele against the early onset of CAD (Kleber, et al., 2010). Many studies 
have shown that SNP 599389 along with its association with CAD has been 
also associated with LDL metabolism due to its chromosomal location in the 
vicinity of sortilin gene, which recently was demonstrated to be involved in 
the receptor-mediated binding lipoprotein lipase on the surface of 
adipocytes(Nielsen, 1999).         
Comparison of SNP 599389 genotypes with CAD categories in different 
arrangement did not allow the detection of significant association between 
the SNP and the disease in our population. Even in the allelic comparison 
model, no association was observed. When investigating for association 
between the SNP 599389 and early onset of CAD a statistically significant 
association has been observed (p=0.03). This significance increased when 
age was considered as categorical variable (p=0.016). Moreover, the 
heterozygote group comprises the lowest age of onset (58.11 years). The 
protective effect against early onset of the disease correlated with this SNP, 
maybe due to linkage disequilibrium with several other variants within the 
chromosomal location 1p13.3 which harbors 4 genes one of which is the 
Sortillin gene implicated in lipid metabolism.  
Concerning SNP 12487736, none of the genotypic and allelic comparisons 
made within several CAD categories and in different rearrangements, led to 
significant results. Our results were in accordance with Chen and colleagues 
who could not identify an association between rs12487736 and premature 
CAD in a Chinese population(Chen, 2010). Different results were reported in 
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 another study where the role of this SNP and its implication in sudden 
cardiac death in young finish population were confirmed(Fan, et al., 2008). 
Furthermore, this SNP was associated with increased risk of early onset of 
MI among American males (Chen, 2010) and was also found to possess an 
important role in lipid metabolism(Iwaki, 1999). It is found on the SCAP 
gene that is implicated in the activation of SREBF gene which has a crucial 
function in activating a number of other genes involved in lipid metabolism 
and regulation of low density lipoprotein (Chen, 2010). Plasma cholesterol 
level may not be a good indicator of intracellular sterol thus this variant may 
not influence metabolic and clinical characteristics. In addition, early onset 
of CAD maybe associated with other metabolic disorders. We could not 
validate the association of the studied SNP and early onset of CAD in our 
Lebanese population. This discrepancy may be due to difference in genotype 
and allele frequencies of rs12487736 in subjects with different geographic 
and ethnic distribution or differences in clinical characteristics.  
 
In the third part we aimed to examine the impacts of genetics on coronary 
artery disease and young age at diagnosis. Further, we seek to understand the 
relationships between early diagnosis of CAD, the genetic conditions 
promoting early diagnosis, and risk factors of CAD, such as hyperlipidemia, 
diabetes, and hypertension. These genetic relationships are inferred by the 
interrelation of family history and consanguinity. The impact of family 
history includes both life-style and genetic components. Consanguinity 
promotes homozygosity, but without family history, homozygosity is less 
likely to include genes that are deleterious to coronary health, while 
consanguinity in the presence of a family history of disease is much more 
likely to reflect homozygous enhancement of pathogenic genetics.  
Alternatively, consanguinity can also mark subpopulations where drift can 
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 promote and sustain more deleterious mutations.  Therefore, the relationship 
between the impact of consanguinity on risk with and without family history 
might be used to factor out population, behavioral and environmental 
impacts of family history or consanguineous culture, and the genetic impact. 
Tests for confounding effects and interactions due to sex, the presence of 
interactions, and logistic regressions comparing impacts for family history of 
CAD, consanguinity, and diagnosed risk factors on young age at diagnosis of 
CAD were computed.  A test template designed in this study to control for 
confounding correlation involving sex by stratification, as well as 
interactions among risk conditions was constructed, which included 
measures of how much of the risk factors could be attributable to family 
history of CAD and consanguinity, as well as measures of how much the 
presence and absence of these factors may have impacted the effect of risk of 
family history and consanguinity on early diagnosis.   
A test measuring the strength of the interaction between risk factors and 
consanguinity was inconclusive in this data set, with very wide error bars 
associated with the small sample sizes available among the interactive test 
cases. 
Though diabetes, hypertension, and hyperlipidemia are strong predictors of 
CAD category 3, these results provide strong evidence for the impact of 
consanguinity and family history, on early diagnosis of CAD among CAD 
category 3 subjects that are the results of socio-cultural ethnic endogamy in 
the Lebanese population. Hence, the impact of genetics on CAD is strongly 
dependent on population-specific factors, ranging from rare in outbred 
Caucasians patient, to high in Lebanese consanguineous families, and 
especially those with family history of the disease. Some susceptibility 
variants may also have a strong impact in other populations or patients’ 
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 subgroups with specific clinical manifestation of the disease like early 
diagnosis.  
 
5. Limitations and strengths: 
 
5.1 Limitations 
 
 Subjects were selected among those referred for catheterization.  
Catheterization was not performed on a control population since this is an 
invasive procedure whose implementation without need would challenge 
ethical standards. There is therefore a potential selection bias of age 
according to perceived risk.   
It has been documented that MPO levels increase in the first 2 hours after 
onset of symptoms in ACS patients, and then decrease promptly. Therefore a 
delay in blood collection may be a source of bias (Brennan, 2003). 
 
5.2 Strengths 
One of the strengths of our study is in the unambiguous phenotypic 
characterization that is based on a stringent case-control definition criteria 
where the percent of stenosis in all four coronary arteries was determined 
based on angiographic visualization. This study design ensured the 
participants belong to a homogeneous population with relatively similar 
environmental exposures.  
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 6. Conclusion 
 
Coronary artery disease is a result of complex interactions among genetic, 
metabolic, and environmental risk factors. 
In this study we assessed the role of MPO as biomarker of stenosis severity 
in ACS patients, we tried to replicate findings in literature concerning SNPs 
599389 and 12477386 and their association with early onset of CAD and we 
also evaluated consanguinity as a risk for early onset of CAD in the 
Lebanese population.    
Our results showed a lack of association of MPO serum levels and 
atherosclerotic severity. Also, we were able to demonstrate that SNP 599389 
minor allele G is implicated in protection against early onset of CAD. 
Furthermore, we found that consanguinity does not impact general risk for 
CAD.  This suggests that both the genetic and the social components to 
consanguinity do not significantly affect CAD expression. But increase early 
diagnosis of CAD significantly.  
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